CAL (CHRONIC AIRFLOW LIMITATION) BENEFITS FROM SMOKING CESSATION
|
Clinical Bottom Lines:
|
Appraised by: HN Lee, December 6th 1992
The Evidence:
|
Study and Length of Follow-up |
Cohort (n) |
FEV1 decline |
Survival |
|
Postma et al [1] Follow-up: 2-21 years |
59 smokers 22 smokers who quit |
87 ± 5 ml/yr 47 ± 7 ml/yr |
not reported |
|
Hughes et al [2]
Follow-up: ave. 3 years |
37 smokers 19 smokers who quit |
54 ± 5 ml/yr 16 ± 9 ml/yr p < .001 |
8/37 = .22 3/19 = .16 p = .60 |
|
Kanner et al [3] Follow-up: 12 years |
21 non-smokers 24 smokers who quit 55 smokers |
Not analyzed |
12 year F/U: 86% survival 79% survival 64% survival |
|
Postma et al [4]
Follow-up: 18 years |
SEVERE COPD (FEV1 < 1.0) 83 smokers 46 smokers who quit |
Not analyzed |
18 year F/U: Mortality Risk Ratio approx 1.4 p < .01 |
|
NIH IPPBT, Anthonisen [5]
Follow-up: 2.5 years |
985 COPD patients
133 lost to follow-up |
Reported as "negative", but no data given. |
Not analyzed |
Comments:
1. Some studies show an increased short-term mortality in the smoking cessation cohort but this is thought to reflect the acute event at the time of inception cohort.
___________________________________________________________________________________________
REFERENCES:
[1] Postma DS et al. Long-term COPD course of lung function. Am Rev Resp Dis 1986;134(2):276-280.
[2] Hughes JA et al. The influence of cigarette smoking and lung function. Q J Med 1982;51(202):115-124.
[3] Kanner RE et al. Predictors of COPD survival. Am J Med 1983;74:249-255.
[4] Postma DS et al. Survival and CAL. Eur J Resp Dis 1985 67(5):360-368.
[5] Anthonisen et al. Prognosis in COPD. Am Rev Resp Dis 1986;133:14-20.
Click here to comment on this CAT |
![]() |